GSK: ViiV submits two-drug regimen application in Europe

(CercleFinance.com) - GlaxoSmithKline's ViiV Healthcare on Friday said that it has filed for European marketing approval of a two-drug regimen treatment of HIV, instead of the traditional three-drug regimen.


GSK's unit has announced submission of a marketing authorisation application to the European Medicines Agency (EMA) for a single-tablet of dolutegravir and lamivudine for the treatment of HIV-1 infection.

The group plans to make a new drug application to the FDA in the US in October.

ViiV Healthcare has been specifically founded in 2009 by GlaxoSmithKline and Pfizer with the aim of developing the treatment of HIV.

Copyright (c) 2018 CercleFinance.com. All rights reserved.